Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Q3 2025 value amounting to $161000.0.

  • Vanda Pharmaceuticals' Capital Expenditures changed 0.0% to $161000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 10982.99%. This contributed to the annual value of $490000.0 for FY2024, which is 2793.73% up from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' Capital Expenditures stood at $161000.0, which was down 0.0% from $299000.0 recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Capital Expenditures registered a high of $436000.0 during Q1 2025, and its lowest value of -$10000.0 during Q3 2021.
  • Its 5-year average for Capital Expenditures is $157894.7, with a median of $148000.0 in 2022.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Capital Expenditures tumbled by 10406.5% in 2021 and then skyrocketed by 612857.14% in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Capital Expenditures stood at $134000.0 in 2021, then skyrocketed by 96.27% to $263000.0 in 2022, then dropped by 3.8% to $253000.0 in 2023, then fell by 15.42% to $214000.0 in 2024, then decreased by 24.77% to $161000.0 in 2025.
  • Its Capital Expenditures was $161000.0 in Q3 2025, compared to $299000.0 in Q2 2025 and $436000.0 in Q1 2025.